Yükleniyor... / Loading...
This study examines the use of Oxycodone in pain management after cesarean delivery using a precision (personalized) approach. It enrolled women over 18 who delivered by cesarean and their infants. It was a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Pregnant Adult women (\>18 y) and their infants * All races * ASA physical status 2 to 3 * Cesarean delivery at UPMC Magee * Planned breast feeding mothers and their infants Exclusion Criteria: * Serious illnesses or condition of either mother or infant precluding ability to participate in study procedures * Multiple gestation pregnancies * Preoperative severe pain and opioid use/misuse * Allergy to oxycodone * Women with opioid use disorder * Any known condition that anticipates neonatal observation in NICU immediately after birth * General anesthesia anticipated or converted intraoperatively * Expected non-viable current gestation or serious neonatal health comorbidities anticipated prior to delivery * Severe neurological disorder: any known untreated or uncontrolled seizure disorder, pre-eclampsia with severe features, pre-eclampsia requiring magnesium, elevated ICP other than benign intracranial hypertension condition, or conditions at the discretion of PI * Liver disease: any known abnormal live function tests, or conditions at the discretion of PI * Renal diseases: any chronic or acute renal insufficiency, or pre-eclampsia diagnosis with abnormal renal function i.e.: severe features, or conditions at the discretion of PI. * Contraindications to neuraxial anesthesia, neuraxial morphine, acetaminophen, or NSAIDs which are standard parts of post-cesarean multimodal analgesia